5 citations
,
February 2014 in “Journal of Liquid Chromatography & Related Technologies” Method accurately measures finasteride and tamsulosin in combined drug form.
88 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” 8 citations
,
August 2016 in “Journal of the European Academy of Dermatology and Venereology” Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
1 citations
,
September 2024 in “IP Indian Journal of Clinical and Experimental Dermatology” Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
January 2025 in “Nanoscale Advances” The nanocomposite effectively targets lung cancer cells without harming normal cells.
1 citations
,
October 2025 in “Ophthalmology Science” Lower doses of topotecan are safe for eyes, but higher doses may harm the retina.
6 citations
,
September 1995 in “The American Journal of Cosmetic Surgery” The new technique PÂTÉ improved the amount of scalp tissue removed in surgeries.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
17 citations
,
October 2023 in “Science Progress” Polycaprolactone and barium titanate composites show promise for use in biomedical applications.
September 2023 in “Journal of the American Academy of Dermatology”
Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
5 citations
,
December 2014 in “Medicine and Pharmacy Reports” Ciproterone acetate improves hair regrowth and acne in most female patients.
May 2026 in “Chemical Engineering Journal” 50 citations
,
January 2008 in “International Journal of Antimicrobial Agents” Alpha-blockers are recommended first for recent CP/CPPS, while antimicrobials are not advised for long-term cases.
7 citations
,
January 2025 in “Journal of Medicinal Chemistry” New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.
88 citations
,
May 2011 in “British Journal of Clinical Pharmacology” High doses of cyproterone acetate are linked to an increased risk of developing meningioma.
42 citations
,
December 1976 in “PubMed” Cyproterone acetate and ethinylestradiol effectively reduce hirsutism and acne in women.
July 2025 in “Ultrasound in Medicine & Biology” UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
September 2004 in “Inpharma Weekly”
September 2022 in “Journal of the American Academy of Dermatology” The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
1 citations
,
April 2018 in “Dermatologic Surgery” May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
9 citations
,
May 2014 in “Clinical Cosmetic and Investigational Dermatology” Using tazarotene with GliSODin improves facial skin more than tazarotene alone.
1 citations
,
February 2025 in “Notulae Scientia Biologicae” Optimized emulgels with Levofloxacin effectively treat eye infections with prolonged drug release and safety.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.